Ars Pharmaceuticals Inc (SPRY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Director Eric Karas - Chief Commercial Officer Kathleen Scott - Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Kevin Holder - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning and welcome to ARS Pharmaceuticals Conference Call.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.
ARS Pharmaceuticals: A Significant Upside Is Expected From neffy
ARS Pharmaceuticals offers significant upside driven by neffy, the only FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. ARS faces near-term pressure from a patent challenge by Lupin, but even pessimistic scenarios suggest the stock is at least fairly valued. Base case fair value is $24.29 (138% upside), while the pessimistic scenario yields $12.25 (20% upside) from current prices around $10.20.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer Kathleen D. Scott - Chief Financial Officer Richard E.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago.
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
